Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2020 Sep;48(9):300060520935309.
doi: 10.1177/0300060520935309.

SLC6A4 gene L/S polymorphism and susceptibility to pulmonary arterial hypertension: a meta-analysis

Feng Zhang  1 , Meiming Yang  2 , Ting Xiao  1 , Yan Hua  1 , Yu Chen  1 , Shasha Xu  1 , Chunping Ni  1
Affiliations
Meta-Analysis

SLC6A4 gene L/S polymorphism and susceptibility to pulmonary arterial hypertension: a meta-analysis

Feng Zhang et al. J Int Med Res. 2020 Sep.

Abstract

Objective: To investigate the association between the solute carrier family 6 member 4 (SLC6A4) gene L/S polymorphism and pulmonary arterial hypertension (PAH).

Methods: The relevant literature was retrieved from the PubMed® database and the data were extracted. STATA® version 12.0 software was used to calculate pooled odds ratios (ORs) and 95% confidence intervals (CI).

Results: Eight case-control studies qualified for inclusion in the meta-analysis. These studies included 1215 cases and 936 control subjects. There was no significant association between the SLC6A4 gene L/S polymorphism and PAH risk in the total population (LL versus SS: OR 1.83, 95% CI 0.95, 3.51; LS versus SS: OR 1.37, 95% CI 0.93, 2.02; dominant model: OR 1.38, 95% CI 0.97, 1.97; recessive model: OR 1.54, 95% CI 0.84, 2.83). Subgroup analysis based on study quality scores and Hardy-Weinberg equilibrium also showed no significant association.

Conclusion: The findings of this meta-analysis suggest that the SLC6A4 gene L/S polymorphism is unlikely to be related to PAH risk. Well-designed studies with more participants will be required to validate these results.

Keywords: 5-hydroxytryptamine transporter; meta-analysis; pulmonary arterial hypertension.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Flow diagram of eligible studies showing the number of citations identified, retrieved and included in the meta-analysis to investigate the relationship between the solute carrier family 6 member 4 (SLC6A4) gene L/S polymorphism and pulmonary arterial hypertension.
Figure 2.
Figure 2.
Forest plot of a meta-analysis to investigate the relationship between the solute carrier family 6 member 4 (SLC6A4) gene L/S polymorphism and pulmonary arterial hypertension. Data are pooled odds ratios (OR) with 95% confidence intervals (CI) determined using a random-effects model. Error bars indicate the 95% CIs.,–,–
Figure 3.
Figure 3.
Sensitivity analysis of the relationship between the solute carrier family 6 member 4 (SLC6A4) gene L/S polymorphism and pulmonary arterial hypertension.
Figure 4.
Figure 4.
Begg’s funnel plot of studies included in a meta-analysis to investigate the relationship between the solute carrier family 6 member 4 (SLC6A4) gene L/S polymorphism and pulmonary arterial hypertension to test for publication bias. Area of each circle represents the contribution of the study to the pooled odds ratio (OR).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. McGoon MD, Benza RL, Escribano-Subias P, et al. Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol 2013; 62: D51–D59. - PubMed
    1. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 2015; 46: 903–975. - PubMed
    1. Stacher E, Graham BB, Hunt JM, et al. Modern age pathology of pulmonary arterial hypertension. Am J Respir Crit Care Med 2012; 186: 261–272. - PMC - PubMed
    1. Ulrich S, Szamalek-Hoegel J, Hersberger M, et al. Sequence variants in BMPR2 and genes involved in the serotonin and nitric oxide pathways in idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: relation to clinical parameters and comparison with left heart disease. Respiration 2010; 79: 279–287. - PubMed
    1. Fink KB, Gothert M. 5-HT receptor regulation of neurotransmitter release. Pharmacol Rev 2007; 59: 360–417. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources